Hiv Aids

From hugs to food to tattoos: Debunking 16 dangerous myths about HIV

From casual contact and mosquito bites to tattoos, pregnancy, PrEP, and treatment, specialists debunk the misconceptions that fuel stigma and delay diagnosis

How poor diabetes management increases complications in people with HIV

Experts warn that poor sugar control pushes HIV-related health risks higher, leading to faster progression of heart, kidney and nerve problems

Can HIV be cured? New research shows long-term remission may be closer

Early trial results show that combining antibodies and T-cells helped some people living with HIV maintain viral control for months without daily ART, raising cautious hope for long-term remission

How soon HIV symptoms appear, and why most people don't notice them

Health agencies warn that HIV begins replicating within hours of exposure and is most infectious in the first weeks, even when there are no symptoms or only mild, flu-like signs

Datanomics: Injecting drug users remain at highest HIV risk in India

India marks World AIDS Day with HIV prevalence at 0.2%, highest among injecting drug users, even as Mizoram continues to report rates far above the national average

World AIDS Day 2025: Theme, history, significance, facts you need to know

As the world marks World AIDS Day 2025, the focus is on transforming the HIV response through stronger funding, inclusive care and renewed commitment to ending AIDS by 2030

Birth control in HIV: What women can safely use and what doctors warn about

HIV-positive women have several safe birth-control options, but viral load, ART interactions, treatment stability still guide what doctors recommend for reliable contraception and partner protection

World AIDS Day 2025: India halves new HIV cases, AIDS deaths drop over 80%

India's latest HIV report shows sharp declines in new infections, AIDS-related deaths and mother-to-child transmission, reflecting expanding testing, treatment and stronger public health systems

Global HIV response in crisis due to severe funding collapse, warns UNAIDS

With HIV services shrinking across countries and prevention tools falling out of reach, UNAIDS says the world is at a critical juncture and must renew its commitment to end AIDS

Sex education should be provided to children from younger age: SC

Sex education should be provided to children from a younger age, and not Class IX onwards, the Supreme Court has said. A bench of Justices Sanjay Kumar and Alok Aradhe said sex education should be part of the curriculum in higher secondary schools so that young adolescents are made aware of the hormonal changes that come with puberty. "We are of the opinion that sex education should be provided to children from a younger age and not Class IX onwards. It is for the authorities concerned to apply their mind and take corrective measures, so that children are informed of the changes that happen after puberty, and the care and cautions to be taken in relation thereto," the bench said. The top court made the observations while granting bail to a 15-year-old boy accused of offences under sections 376 (rape) and 506 (criminal intimidation) of the IPC, and Section 6 (aggravated penetrative sexual assault) of the Protection of Children from Sexual Offences (POCSO) Act. The apex court earlier

'Bluetoothing': Blood-sharing drug trend fuels alarming global HIV surge

The practice, in which users inject the blood of already intoxicated individuals, has fuelled one of the fastest-growing HIV epidemics in the Pacific and grown widespread in South Africa

One shot every six months: India could change HIV prevention forever

A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of generic production

World sexual health day 2025: Championing sexual justice for all

The global observance reminds us that sexual health is a human right, calling for safe, respectful and informed choices free from stigma and inequality

EU clears twice-yearly HIV shot lenacapavir, paving way for Europe rollout

The drug, called lenacapavir, is a form of pre-exposure prophylaxis (PrEP) that prevents the virus from replicating and spreading within the body

EU clears twice-yearly HIV shot lenacapavir, paving way for Europe rollout

The drug, called lenacapavir, is a form of pre-exposure prophylaxis (PrEP) that prevents the virus from replicating and spreading within the body

Why men are more likely to die from diabetes, hypertension and HIV

A global study in PLOS Medicine shows men have higher death rates from diabetes, hypertension and HIV/AIDS, largely due to risky lifestyles and lower healthcare use

WHO approves injectable HIV drug lenacapavir for high-risk communities

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk groups, as global HIV prevention efforts face funding setbacks

WHO approves injectable HIV drug lenacapavir for high-risk communities

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk groups, as global HIV prevention efforts face funding setbacks

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. The Hyderabad-based drugmaker has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare, the company said in a statement. The agreement allows Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets, it added. This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months. "We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to t

US aid cuts pause HIV vaccine research in S Africa, to have global impact

Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were high for another step toward limiting one of history's deadliest pandemics. Then the email arrived. Stop all work, it said. The United States under the Trump administration was withdrawing all its funding. The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the world. Their research project, called BRILLIANT, was meant to be the latest to draw on the region's genetic diversity and deep expertise in the hope of benefiting people everywhere. But the $46 million from the US for the project was disappearing, part of the dismantling of foreign aid by the world's biggest donor earlier this year as President Donald Trump announced a focus on priorities at home. South Africa hit hard by aid cuts South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the ..